The Role of ddPCR™ Technology in Sensitive MRD Monitoring in Research Settings
MRD monitoring has evolved from early molecular assays to liquid biopsy approaches that detect tumor signals in blood or tissue. Because these signals are often present at extremely low levels, MRD research requires highly sensitive and reproducible quantification. By partitioning each sample into tens of thousands of individual droplets, Droplet Digital™ PCR (ddPCR) technology delivers the sensitivity and absolute quantification needed to detect rare targets that may fall at or below the quantification limits of conventional assays.
In this white paper, you will learn about:
- How MRD monitoring has evolved from early feasibility studies to today’s ctDNA-based approaches
- The expanding role of MRD in hematologic malignancies and solid-tumor research
- Why ddPCR technology is well suited for detecting and quantifying rare targets in research samples
- How ddPCR technology and next-generation sequencing can serve complementary roles
- What greater standardization and analytical rigor could mean for the future of MRD research
Download the White Paper
Share a little information with us to download the entire white paper now.
Featured Content
Recommended Features
Oncology Solutions from Bench to Bedside
Advance oncology research from discovery to clinical application with precise, reliable tools designed to accelerate translation, refine research approaches, and support every stage of your research journey.
Meet the Next Evolution of ddPCR Solutions
Explore Bio-Rad’s comprehensive portfolio of Droplet Digital™ PCR (ddPCR™) solutions, including our new QX700™ Series Systems, backed by world-class expertise and more than 12,000 publications to support your research.
Improving NGS Workflows with ddPCR Technology
Enhance NGS workflows with Droplet Digital™ PCR (ddPCR™) technology for precise quantification and orthogonal validation. Download the white paper to learn more.